BeiGene Announces that the Phase 3 Trial of Tislelizumab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysis

Daniel Sontupe
Market Access

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment

Matt Turner
Patient Affordability

Frank Burrell
Scientific Storytelling

Bud Bilanich
Success Coach

Pat Purcell
Meeting Engagement

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence

Liz Kane
Impactful Strategy

Brenda Snow
Authentic Patient Voice